CVS Caremark to add Zydus Zituvio, combination products to its template formulary
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-01-07 10:30 GMT | Update On 2025-01-07 10:30 GMT
Advertisement
Ahmedabad: Zydus Lifesciences Ltd, a global healthcare company announced that it has entered into an agreement with CVS Caremark, a CVS Health company to add Zituvio, Zituvimet and Zituvimet XR (Sitagliptin | Sitagliptin and Metformin Hydrochloride) tablets to its template formulary.
CVS Caremark will add Zydus’ Zituvio and combination products to its template formulary starting January 1, 2025.
Zituvio and combination products include Zituvio (sitagliptin), Zituvimet (sitagliptin and metformin hydrochloride) and Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets. These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route.
The Zituvio range of products contain active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.